Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYTĀ® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

Event details

Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM) (oral presentation)

Dec 2, 2018

Avapritinib - SM

Agenda

American Society of Hematology (ASH) Annual Meeting